Details

Autor(en) / Beteiligte

• Ravipaty, Shobha
• Wu, Wenfang
• Dalvi, Aditee
• Tanna, Nikunj
• Andreazi, Joe
• Friss, Tracey
• Klotz, Allison
• Liao, Chenchen
• Garren, Jeonifer
• Schofield, Sally
• Diamandis, Eleftherios P.
• Klein, Eric A.
• Dobi, Albert
• Srivastava, Shiv
• Tekumalla, Poornima
• Kiebish, Michael A.
• Vishnudas, Vivek K.
• Sarangarajan, Rangaprasad
• Narain, Niven R.
• Akmaev, Viatcheslav

Titel

Abstract 3826: Clinical validation of a serum protein panel (FLNA, FLNB and KRT19) for diagnosis and prognosis of prostate cancer

Ist Teil von

• Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3826-3826

Erscheinungsjahr

2017

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• Abstract Background: Prostate cancer (PrCa) is a leading cause of cancer deaths in males in the US. Current tests of prostate-specific antigen (PSA) screening and the diagnostic prostate biopsy are often inconclusive. Many patients with a PSA positive blood test often undergo invasive repeat biopsy procedures. Additionally, there is a need for diagnostic tests that differentiate between low and high-risk cancers. This study reports on the development of a novel serum protein panel of three PrCa biomarkers, Filamin A, Filamin B and Keratin-19 (FLNA, FLNB and KRT19) using multivariate models for disease screening and prognosis. Methods: ELISA and IPMRM (LC-MS/MS) based assays were developed and analytically validated by quantitative measurements of the biomarkers in serum. Retrospectively collected and clinically annotated serum samples with PSA values and Gleason scores (GS) were analyzed from 503 subjects who underwent prostate biopsy, and showed no evidence of cancer with or without indication of prostatic hyperplasia, or had a definitive pathology diagnosis of prostatic adenocarcinoma. Probit linear regression models were used to combine the analytes into score functions to address the following clinical questions: does the biomarker test augment PSA for population screening? Can aggressive disease be differentiated from lower risk disease, and can the panel discriminate between benign prostate hyperplasia (BPH) and PrCa? Results: Table 1: Berg PrCa Panel AUC summary for the four clinical indications. Conclusion: As shown in Table 1, modelling of the data demonstrated that the new PrCa biomarkers and PSA in combination were better than PSA alone in identifying PrCa, improved the prediction of high and low risk disease, and improved prediction of BPH versus PrCa. Citation Format: Shobha Ravipaty, Wenfang Wu, Aditee Dalvi, Nikunj Tanna, Joe Andreazi, Tracey Friss, Allison Klotz, Chenchen Liao, Jeonifer Garren, Sally Schofield, Eleftherios P. Diamandis, Eric A. Klein, Albert Dobi, Shiv Srivastava, Poornima Tekumalla, Michael A. Kiebish, Vivek K. Vishnudas, Rangaprasad Sarangarajan, Niven R. Narain, Viatcheslav Akmaev. Clinical validation of a serum protein panel (FLNA, FLNB and KRT19) for diagnosis and prognosis of prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3826. doi:10.1158/1538-7445.AM2017-3826